Open Access Journal of Toxicology
ISSN 2474-7599

Juniper Publishers
key to the Researchers

Mini Review
Volume 5 Issue 3 - November 2022
DOI: 10.19080/OAJT.2022.05.555664

Open Acc J of Toxicol

Advances in Lipotoxicity Research on Hepatocellular Carcinoma

Ming Han Wang, Jun Yuan Han and Quanjun Wang*

Department of Toxicology and Drug Research, Academy of Military Medical Sciences, China

Submission: August 05, 2022; **Published:** November 01, 2022

***Corresponding author**: Quanjun Wang Department of Toxicology and Drug Research, Academy of Military Medical Sciences, China

Abstract

Hepatocellular carcinoma (HCC), a fifth most continual diagnosed cancer, acquires large amounts of free fatty acids (FAs) to promote cell growth. But how the cancer avoids lipotoxicity is unknown. Here, we discussed some lip toxicity research in HCC. Targeting molecules related to lipotoxicity could be a promising therapeutic approach for HCC.

Keywords: Hepatocellular carcinoma; Endoplasmic reticulum; Altered fatty acid; Free fatty acids; Cholesterol ester; Tricarboxylic acid

Abbreviations:HCC: Hepatocellular Carcinoma; ER: Endoplasmic Reticulum; FA: Fatty Acid; FFAs: Free Fatty Acids; CE: Cholesterol Ester; TA: Tricarboxylic Acid

Global Impact of HCC

Hepatocellular Carcinoma (HCC) is the fifth most continual diagnosed cancer and epidemiological studies have authenticated obesity as a crucial risk factor in its development, recently [1-3]. Endoplasmic Reticulum (ER) and oxidative stress, the dysregulation of adipokines, altered gut microbiota and elevated proinflammatory cytokines have been suggested feasible mechanisms underlie obesity-mediated hepatocarcinogenesis, but the process remains dimness [4-8]. Tumour cells undergo typical metabolic changes to fit to their local environment, what is called "metabolic reprogramming" [9]. The most well-studied of these changes is the Warburg effect, in which tumour cells don't use the normal cellular pathway of mitochondrial oxidative phosphorylation but aerobic glycolysis to exert the energy needed for the synthesis of proteins, nucleic acids and lipids [10]. Altered Fatty Acid (FA) metabolism is another distinction of tumour cells [11].

Lipotoxicity

Lipotoxicity means exposure and accumulation of various lipid species which may cause cellular toxicity or proinflammatory and profibrotic [12]. Relatively small quantities of lipotoxic lipid may exert large negative impact on HCC. While, some others, like omega-3 fatty acids, may decrease lipotoxicity and show a beneficial effect [13]. Potentially lipotoxic molecules include Free Fatty Acids (FFAs) and their derivatives, ceramides [14] diacylglycerol [15] as well ascholesterol [16-18]. FFAs may act in KCs (the resident macrophages of the liver), stellate cells (the cells responsible for most hepatic fibrosis) and hepatocytes [the cells that store most hepatic lipid, including cholesterol and Cholesterol Ester (CE)] and affect insulin signaling, impair membrane function and result in apoptosis [19].

Lipotoxicity Research in HCC

Many studies have reported that lipid metabolism is significantly changed, especially FA synthesis, which is obviously elevated in various types of tumours [20-22]. FAs are synthesized de novo in gross tumour cells, especially in HCC [11,21]. They are essential lipids in cells as they constitute the major structural components of membrane lipids, serve as signalling molecules, an energy source through mitochondria-mediated b-oxidation and Tricarboxylic Acid (TCA) cycle catabolism, storage compounds and incorporation into the cell membrane. However, the enhancive intake of dietary FAs participates with the lipolysis of visceral adipose tissue result in enormous exogenous FA supplies to hepatocytes though the portal vein in obesity [23-26]. This is an extremely feature environment lipid-rich condition for liver cancer, but how the pernicious cells accommodate to it and use it for their recreation is still obscure. Targeting molecules related to lipo toxicity could be a promising therapeutic approach for HCC..

References

1. El Serag HB (2011) Hepatocellular carcinoma. N Engl J Med 365(12): 1118-1127.
2. Calle EE, Rodriguez C, Walker Thurmond K, Michael J (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348(17): 1625-1638.
3. Fujiwara N, Nakagawa H, Kudo Y, Tateishi R, Taguri M, et al. (2015) Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma. J Hepatol 63(1): 131-140.
4. Park EJ, Lee JH, Yu GY, He G, Yu GY, et al. (2010) Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140(2): 197-208.
5. Tilg H, Hotamisligil GS (2006) Nonalcoholic fatty liver disease: Cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology 131(3): 934-945.
6. Nakagawa H, Umemura A, Taniguchi K, Font Burgada J, Dhar D, et al. (2014) ER stress cooperates with hyper nutrition to trigger TNF-dependent spontaneous HCC development. Cancer Cell 26(3): 331-343.
7. Yoshimoto S, Loo TM, Atarashi K, Hiroaki Kanda, Seidai Sato, et al. (2013) Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 499(7456): 97-101.
8. Nakagawa H (2015) Recent advances in mouse models of obesity- and nonalcoholic steatohepatitis associated hepatocarcinogenesis. World J Hepatol 7(17): 2110-2118.
9. Ward PS, Thompson CB (2012) Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 21(3): 297-308.
10. Vander Heiden MG, Cantley LC, Thompson CB. (2009) Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 324(5930): 1029-1033.
11. Currie E, Schulze A, Zechner R, Tobias CW, Farese RV, et al. (2013) Cellular fatty acid metabolism and cancer. Cell Metab 18(2):153-161.
12. Neuschwander Tetri BA (2010) Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 52(2): 774-788.
13. Scorletti E, Byrne CD (2013) Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease. Annu Rev Nutr 33: 231-248.
14. Chaurasia B, Summers SA (2015) Ceramides–lipotoxicinducers of metabolic disorders. Trends Endocrinol Metab 26(10): 538-550.
15. Kumashiro N, Erion DM, Zhang D, Kahn M, Beddow SA, et al. (2011) Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc Natl Acad.Sci USA 108(39): 16381-16385.
16. Scorletti E, Byrne CD (2013) Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease. Annu Rev Nutr 33: 231-248.
17. Musso G, Gambino R, Cassader M (2013) Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. Prog. Lipid Res 52(1): 175-191.
18. Arguello G, Balboa E, Arrese M, Zanlungo S (2015) Recent insights on the role of cholesterol in non-alcoholic fatty liver disease. Biochim Biophys Acta 1852(9): 1765-1778.
19. Tabas I (2002) Consequences of cellular cholesterol accumulation: basic concepts and physiological implications. J Clin Invest 110(7): 905-911.
20. Cheng C, Geng F, Cheng X, Guo D (2018) Lipid metabolism reprogramming and its potential targets in cancer. Cancer Commun (Lond) 38(1): 27.
21. Guo D, Bell EH, Mischel P, Chakravarti A (2014) Targeting SREBP-1-driven lipid metabolism to treat cancer. Curr Pharm Des 20(15): 2619-2626.
22. Menendez JA, Lupu R (2007) Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 7: 763-777.
23. Budhu A, Roessler S, Zhao X, Yu Z, Forgues M, et al. (2013) Integrated metabolite and gene expression profiles identify lipid biomarkers associated with progression of hepatocellular carcinoma and patient outcomes. Gastroenterology 144(5): 1066-1075.
24. Carracedo A, Cantley LC, Pandolfi PP (2013) Cancer metabolism: fatty acid oxidation in the limelight. Nat Rev Cancer 13(4): 227-232.
25. Currie E, Schulze A, Zechner R, Walther TC, Farese RV (2013) Cellular fatty acid metabolism and cancer. Cell Metab 18(2): 153-161.
26. Qu Q, Zeng F, Liu X, Wang QJ, Deng F (2016) Fatty acid oxidation and carnitine palmitoyl transferase I: emerging therapeutic targets in cancer. Cell Death Dis 7(5): e2226.

DOI: 10.19080/OAJT.2022.05.555664

How to cite this article: Ming H W, Jun Y H, Quanjun W. Advances in Lipotoxicity Research on Hepatocellular Carcinoma. Open Acc J of Toxicol. 2022; 5(3):555664. DOI: 10.19080/OAJT.2022.05.555664